<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212898</url>
  </required_header>
  <id_info>
    <org_study_id>SFalamic</org_study_id>
    <nct_id>NCT03212898</nct_id>
  </id_info>
  <brief_title>Pharmacist Interventions in Rural Elderly Warfarin Patients</brief_title>
  <official_title>The Influence of Pharmacist Interventions on the Effectiveness of Warfarin Treatment in Elderly Patients From Rural Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Slaven Falamić</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Slaven Falamić</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study goal is to explore the influence of pharmacist interventions on the
      effectiveness of warfarin treatment in a specific subpopulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in therapeutic range (TTR)</measure>
    <time_frame>6 months</time_frame>
    <description>Time in therapeutic range by Rosendaal method (percentage of time in therapeutic range)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the difference in number and types of adverse drug reactions between the intervention and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adverse drug reaction</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the difference in time to adverse drug reactions between the intervention and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International randomised ratio</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the difference in patterns of the International randomised ratio between the intervention and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the difference in adherence between the intervention and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the difference of the quality of life in the intervention and the control group at the beginning and the end of the study (validated Croatian version of DUKE - Duke anticoagulation satisfaction scale questionaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and influence of clinically significant drug interactions</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the incidence of clinically significant drug interactions (defined by the Lexicomp-interact base as degree C and D of clinical significance) and influence of drug interactions on the effectiveness and safety of treatment between the intervention and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake of vitamin K</measure>
    <time_frame>6 months</time_frame>
    <description>Changes of dietary intake of vitamin K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of pharmacist's intervention by the general practitioners</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the rate of acceptance of pharmacist's interventions by the general practitioners</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Thrombosis</condition>
  <condition>Cardiac Failure</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specific pharmacist-led anticoagulation care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive usual care; no interventions will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anticoagulation care</intervention_name>
    <description>Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥65 years

          -  Living site of participant outside the city eg. rural site

          -  Expected duration of warfarin therapy at least 6 months from the inclusion in the
             study and 3 months before

        Exclusion Criteria:

          -  Hospitalization

          -  Vegetarianism

          -  Patients not able to provide an informed consent

          -  The use of drug that has an X level of clinical significance of interaction with
             warfarin according to Lexicomp interact base
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Slaven Falamić, MPharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacy Branka Marušić</affiliation>
  </overall_official>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Slaven Falamić</investigator_affiliation>
    <investigator_full_name>Slaven Falamić</investigator_full_name>
    <investigator_title>Slaven Falamić,MPharm, Prinicipal-Investigator</investigator_title>
  </responsible_party>
  <keyword>pharmacist interventions, warfarin, elderly rural patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

